Pediatric Non-Hodgkin Lymphoma: A Retrospective 7-Year Experience in Children & Adolescents with Non-Hodgkin Lymphoma Treated in King Fahad Medical City (KFMC)

Read  full  paper  at:http://www.scirp.org/journal/PaperInformation.aspx?PaperID=55425#.VSX4II7nbeo

Home > Journals > Medicine & Healthcare > JCT

JCT> Vol.6 No.4, April 2015 Share on facebookShare on twitter Share on emailShare on print More Sharing Services2

Open   Access

Pediatric Non-Hodgkin Lymphoma: A Retrospective 7-Year Experience in Children & Adolescents with Non-Hodgkin Lymphoma Treated in King Fahad Medical City (KFMC)

Download as PDF (Size:1793KB)     PP. 299-314

DOI: 10.4236/jct.2015.64033    72 Downloads   104 Views

Author(s)    Leave a comment

Nahla Ali Mobark1*, Suha A. Tashkandi2, Wafa Al Shakweer3, Khalid Al Saidi2, Suha A. Fataftah2, Mohammed M. Al Nemer1, Awatif Eid Al Enazy1, Mohammed Rayis1, Mohammed Waleed Ballourah1, Othman Mosleh1, Zaheer Ullah1, Fahad El Manjomi1, Musa Al Harbi1

Affiliation(s)

1Department of Pediatric Hematology and Oncology, Comprehensive Cancer Centre, KFMC, Riyadh, Saudi Arabia.
2Department of Cytogenetic and Molecular Cytogenetic Laboratory, KFMC, Riyadh, Saudi Arabia.
3Department of Anatomical Pathology, KFMC, Riyadh, Saudi Arabia.

ABSTRACT

Background: Non-Hodgkin’s lymphoma is an aggressive malignant disease in children and adolescents. Although it is the fourth most common malignancy in Saudi children as reported in Saudi cancer registry, less information is available about pediatric Non-Hodgkin lymphoma and its outcome in Saudi Arabia. Study Objectives: To provide demographic data, disease characteristics, treatment protocol, toxicity and outcome of treatment in children & adolescents with Non-Hodgkin’s lymphoma treated at KFMC. This study will form base line for future studies about pediatric Non-Hodgkin’s lymphoma in KFMC, which may help to improve outcome for children with cancer in Saudi Arabia. Study Patients and Method: We retrospectively analyzed 28 children and adolescents diagnosed to have Non-Hodgkin’s lymphoma at KFMC between December 2006 and December 2013, followed-up through June 2014. Results: Of the 28 patients, 10 (35.7%) girls and 18 (64.3%) boys, the male-to-female ratio was 1.8; 1. The median age at time of diagnosis was 6.4 years old (range 2.0 to 13.0 years old). The majority of patients (64.3%) were aged between 5 and 12 years old. Burkitt’s lymphoma BL/BLL was the most common pathological subtype (60.7%), and DLBCL was the second most common subtype (21.4%). Abdominal and Retroperitoneal involvement was the most common primary site (78.6%) including the ileocaecal region. Most of the children presented with advanced Stage III and IV (75%), Cytogenetic study which screens specifically for the t (8; 14) (q24; q32) a characteristic genetic feature of Burkitt’s Lymphoma was obtained from 21 patients, variant rearrangement was observed in 3/21 samples and complex chromosomes karyotype in addition to IGH/MYC rearrangement was observed in 2/21 samples. Those patients presented with very aggressive lymphoma and combined BM and CNS involvement. We use the French-American-British Mature B-Cell Lymphoma 96 Protocol (FAB LMB 96) for treatment fornewly diagnosed Mature B-Cell type NHL and high risk ALL CCG 1961 Protocol for lymphoblastic lymphoma and international Anaplastic Large Cell Lymphoma 99 Study Protocol for ALCL. The median follow-up in patients not experiencing an adverse event was 53.1 months. The estimated 3-year EFE and OS rates in the entire cohort of patients with newly diagnosed NHL treated in the KFMC were 85.2% and 89.2% respectively; Overall survival (OS) rate of patients with mature B-cell-NHL was 88.9%. Conclusion: The outcomes and survival in our small series appeared to be excellent compared with those reported in other international trials even though most of our patients presented in advanced stage of the disease. We feel that the importance of the current study is to document the relative distribution of various types of pediatric non-Hodgkin’s lymphomas and age-specific distribution in different Histological subtypes.

KEYWORDS

Non-Hodgkin Lymphoma, Disease, Patients, Children and Adolescents

Cite this paper

Mobark, N. , Tashkandi, S. , Shakweer, W. , Saidi, K. , Fataftah, S. , Nemer, M. , Enazy, A. , Rayis, M. , Ballourah, M. , Mosleh, O. , Ullah, Z. , Manjomi, F. and Harbi, M. (2015) Pediatric Non-Hodgkin Lymphoma: A Retrospective 7-Year Experience in Children & Adolescents with Non-Hodgkin Lymphoma Treated in King Fahad Medical City (KFMC). Journal of Cancer Therapy, 6, 299-314. doi: 10.4236/jct.2015.64033.

References

[1] The Saudi Cancer Registry (SCR).
http://www.scr.org.sa
[2] Perkins, S.L., Segal, G.H. and Kjeldsberg, C.R. (1995) Classification of Non-Hodgkin’s Lymphomas in Children. Seminars in Diagnostic Pathology, 12, 303-313.
[3] Atra, A., Gerrard, M., Hobson, R., Imeson, J.D., Ashley, S. and Pinkerton, C.R. (1998) Improved Cure Rate in Children with B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Stage IV B-Cell Non-Hodgkin’s Lymphoma (B-NHL): Results of the UKCCSG 9003 Protocol. British Journal of Cancer, 77, 2281-2285.
http://dx.doi.org/10.1038/bjc.1998.379
[4] Bowman, W.P., Shuster, J.J., Cook, B., Griffin, T., Behm, F., Pullen, J., et al. (1996) Improved Survival for Children with B-Cell Acute Lymphoblastic Leukemia and Stage IV Small Non Cleaved-Cell Lymphoma: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 14, 1252-1261.
[5] Brecher, M.L., Schwenn, M.R., Coppes, M.J., Bowman, W.P., Link, M.P., Berard, C.W., et al. (1997) Fractionated Cyclophosphamide and Back to Back High Dose Methotrexate and Cytosine Arabinoside Improves Outcome in Patients with Stage III High Grade Small Non-Cleaved Cell Lymphomas (snccl): A Randomized Trial of the Pediatric Oncology Group. Medical and Pediatric Oncology, 29, 526-533.
http://dx.doi.org/10.1002/(SICI)1096-911X(199712)29:6<526::AID-MPO2>3.0.CO;2-M
[6] Cairo, M.S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C.R., Michon, J., et al. (2007) Results of a Randomized International Study of High-Risk Central Nervous System B Non-Hodgkin Lymphoma and B Acute Lymphoblastic Leukemia in Children and Adolescents. Blood, 109, 2736-2743.
[7] Anon (2000) Cuneo, a Classification of B-cell Non-Hodgkin’s Lymphomas (NHL). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 4, 24-26.
http://AtlasGeneticsOncology.org/Anomalies/BNHLClassifID2067.html
[8] Dave, B.J., Nelson, M. and Sanger, W.G. (2011) Lymphoma Cytogenetic. Clinics in Laboratory Medicine, 31, 725-761.
http://dx.doi.org/10.1016/j.cll.2011.08.001
[9] Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., et al. (1994) A Revised European-American Classification of Lymphoid Neoplasms: A Proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
[10] Murphy, S.B. (1980) Classification, Staging and End Results of Treatment of Childhood Non-Hodgkin’s Lymphomas: Dissimilarities from Lymphomas in Adults. SeminOncol, 7, 332-339
Advertisements

发表评论

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / 更改 )

Twitter picture

You are commenting using your Twitter account. Log Out / 更改 )

Facebook photo

You are commenting using your Facebook account. Log Out / 更改 )

Google+ photo

You are commenting using your Google+ account. Log Out / 更改 )

Connecting to %s